Vaginal Microbiota Transplant (MOTIF)

  • STATUS
    Recruiting
  • End date
    Jun 8, 2024
  • participants needed
    134
  • sponsor
    Douglas Kwon
Updated on 28 February 2022

Summary

This is a randomized trial of vaginal microbiome transplant vs. saline placebo to restore a Lactobacillus dominant vaginal microbial community in women with recurrent bacterial vaginosis.

Description

The investigators propose a randomized, double-blind, placebo-controlled trial to evaluate the safety of vaginal microbiota transplant (VMT) in women with recurrent bacterial vaginosis (BV), and to assess the ability of antibiotic treatment plus vaginal microbiota transplant to establish a Lactobacillus-dominant vaginal community as compared to antibiotic treatment alone. The underlying hypothesis is that the VMT will lead to less inflammation and higher prevalence of vaginal Lactobacillus compared to antibiotics alone. The transplant material will be vaginal fluid collected from healthy donors using a disposable menstrual cup. Donors undergo extensive testing for possible infections to ensure the safety of the donated material.

Study Visits and Procedures: In addition to the pre-screening eligibility phone call and screening visit, there will be two treatment study visits and six post-VMT follow up visits at weeks 3, 5, 7, 11, 15, and 27. The baseline visit will occur within 45 days of the screening visit.

Phone Screen: A brief phone discussion to explain approach and alternatives (see details below in "Technical Methods"). A set of short screening questions will be asked to identify women with clear exclusion criteria for participation.

Visit 1, Screening Visit: At the screening visit, after written informed consent is obtained, the information from the pre-screening questionnaire will be reviewed with the subject and updated as necessary. Blood and vaginal specimens will be collected. The VMT process will be explained in detail and subjects will have the opportunity to inspect an example applicator if interested. Subjects will be counseled not to have vaginal intercourse or insert anything into their vagina from the 72 hours prior to the first transplant dose until 72 hours after the second transplant dose.

  • Review eligibility and understand/see applicator
  • Obtain informed consent
  • Height, weight measurements
  • Subjects will be given information about how to perform vaginal swab collections (see vaginal swab collection document)
  • Physical exam
  • Pelvic exam
  • Screening labs: Complete blood cell count w/ differential, comprehensive metabolic panel, Pap/HPV (human papillomavirus) testing, gonorrhea, chlamydia, trichomonas testing. HIV, Hepatitis B&C, Herpes.
  • Urine pregnancy test
  • Behavior and sexual assessment

Visit 2: Baseline, Week 1 (occurs immediately prior to menses)

  • Self-Administered Vaginal Swab and soft cup collection
  • Blood draw
  • Pelvic Exam: cervical swabs, cytobrush
  • Symptom and Sexual Behavior Assessment
  • Assignment into study groups using block randomization
  • Subjects will be given 7-day course of: Metronidazole 500mg PO every 12 hours

Visit 3: First Transplant Administration, Week 2

  • Self-collected Vaginal Swab and soft cup collection
  • Pelvic Exam: VMT/placebo Administration
  • Symptom and Sexual Behavior Assessment

Visit 4: Second Transplant Administration, Week 2

  • Self-Administered Vaginal Swab
  • Pelvic Exam: VMT/Placebo Administration
  • Symptom and Sexual Behavior Assessment

Visits 5-10: Post-transplant follow ups, Weeks 3, 5, 7, 11, 15, 27

  • Blood draw (visit 7 only)
  • Self-Administered Vaginal Swab
  • Self-Administered soft cup collection (visit 5, 7 & 9)
  • Symptom and Sexual Behavior Assessment
  • Pelvic Exam: cervical swabs, cytobrush (visits 7 & 9)

Details
Condition Recurrent Bacterial Vaginosis
Treatment Sterile Saline, Vaginal microbiome transplant, Oral Metronidazole
Clinical Study IdentifierNCT04046900
SponsorDouglas Kwon
Last Modified on28 February 2022

Eligibility

Yes No Not Sure

Inclusion Criteria

Premenopausal women, 18- 50 years old
Abnormal Nugent score: > 3
History of recurrent bacterial vaginosis (BV) (3 or more documented episodes in past 12 months)
If participating in sexual activity that could lead to pregnancy, study participants must agree to use an effective contraceptive while actively participating in the protocol. At least one of the following methods MUST be used
Condoms (male or female), with or without a spermicidal agent
Intrauterine device (IUD)
Hormonal contraceptive (including oral pills, vaginal ring, implant, injection)

Exclusion Criteria

History of clinically significant vaginal, cervical, or uterine disease including but not limited to: cancer of the female reproductive tract, prior hysterectomy, high grade cervical dysplasia (CIN III), or diagnosed with cervicovaginal infection (with the exception of bacterial vaginosis) within the 30 days prior to the procedure
Allergy to metronidazole
Use of investigational therapies or investigational vaccines within 90 days prior to study entry
Use of any immunomodulatory agents within 30 days prior to study enrollment. Subject taking any of the following medications: systemic steroids (inhaled or nasal steroid therapy is permitted), interleukins, systemic interferons (e.g. local injection of interferon alpha for treatment of HPV is permitted) or systemic chemotherapy
History of coronary artery disease, myocardial infarction, COPD, chronic renal failure, decompensated cirrhosis, or any other condition that in the opinion of the investigator will compromise ability to participate in the study
History of abnormal pap smear within 12 months
Insertion of levonorgestrel-containing IUD within 3 months prior to study entry
Either breastfeeding or pregnant within 24 weeks prior to study entry
Use of probiotics and prebiotics (supplements and products, oral or vaginal) within 30 days of the study. (NOTE: Oral yogurt with live cultures is allowed.)
Routine use of oral antibiotics i.e. daily use for acne, Hidradenitis suppurativa, or regular use for post-coital urinary tract infection prophylaxis within the past 30 days
Taken non-metronidazole antibiotics in last 30 days
BMI > 40
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note